PYGO2

Across TCGA pan-cancer cohorts, PYGO2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PYGO2 data layer compared with 19 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PYGO2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PYGO2 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

PDAC, LSCC, and LUAD are the cancer types where PYGO2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.655	0.926	.005	25	view →
LSCC	OS	Tertile	II,III,IV	0.710	0.946	.001	22	view →
LUAD	OS	Median	All	0.678	1.000	.007	7	view →
HNSC	OS	Median	IV	0.661	0.951	.006	7	view →
CCRCC	OS	Quartile	II,III,IV	0.773	0.995	.020	6	view →
GBM	DFS	Median	All	0.443	0.256	.014	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PYGO2–PDAC (DFS)

Open the PDAC breakdown →